Health Startups Go After 3 Pain Points By Amy Radin Innovators addressing user pain points can influence how plans are selected and healthcare is consumed, but the levers are not easy to move.
U.S. Healthcare Actually Isn't Broken By Dan Munro No, the system is designed to be this messed up. So many people profit from the mess, and they hope the complexity will prevent hard questions.
Consumerism: Good, Bad, Future By Veer Gidwaney If healthcare consumers don’t know what they’re buying or feel they have any say in the matter, are they actually consumers at all?
ACA: Complication for Websites By Alexis Gilroy A recently enacted rule means many healthcare programs have to make websites fully accessible to those with disabilities.
EpiPen Pricing: It’s the System, Stupid By Pramod John As much fun as it is to shame Mylan, a better way to punish the company would be to buy the lower-cost alternatives.
If It Walks Like a Duck, Talks Like a Duck… By David Berg Everyone is talking about the dangers of “opioid addiction,” but here’s the thing: The media – and the public – are missing the point entirely.
How Chatbots Change Open Enrollment By Donna Peeples Chatbots and intelligent automation can streamline service while providing a direct channel for communication with customers.
New, Troubling Healthcare Model By Tom Emerick David Toomey A landmark decision paves the way for a high-cost/high-volume pricing model for healthcare.
Auto Insurance in an Existential Crisis By Stephen Applebaum Alan Demers The 125-year-old, $300 billion U.S. auto insurance industry is caught between runaway inflation and strained consumer wallets.
The Promise of Continuous Underwriting By Bill Deemer Bobby Touran Typically, a risk is underwritten, bound... and forgotten. But new streams of data and automation allow for continuous underwriting.
Convergence and the Insurance Ecosystem By Stephen Applebaum Alan Demers Companies must anticipate the future, innovate beyond their core and transform their capabilities as rapidly as technology allows.
Lemonade's 'Synthetic Agent' Nonsense By Matteo Carbone Desperate for growth, Lemonade produces another howler: A lender receiving a 16% interest rate is presented as a (synthetic) agent.